Depression
EPIX Pharmaceuticals Announces Discontinuation of PRX-00023 Clinical Development Program
Published in Mental Health Law Weekly, April 5th, 2008
"While PRX-00023 continued to show a highly desirable safety and tolerability profile, we are disappointed in the overall results observed in our recently completed Phase 2b trial in major depressive disorder," stated Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. "In light of these results, we have made the strategic decision to discontinue further development of this product candidate."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
More Articles from Mental Health Law Weekly
- Learning Disability
Recent findings in learning disability described by H. Smith and colleagues - Physiology
Reports outline physiology study results from Minot State University - Acid Reflux Disease
Findings from Ernst-Moritz-Arndt University broaden understanding of acid reflux disease - Addiction Medicine
Data from Stanford University, Center for Health Care Evaluation advance knowledge in addiction medicine - Addiction Medicine
Hanley Hope Publishing Introduces Its First Book, ''Men's Healing: a Toolbox for Life'' - Addiction Medicine
New findings from North Dakota State University in the area of addiction medicine described - More from this issue of Mental Health Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
